William N. Levine, MD to Present Catalyst CSR™ Total Shoulder System at American Shoulder and Elbow Surgeons 2019 Annual Meeting

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, today announced that William N. Levine, MD will be presenting on the Catalyst CSR Total Shoulder System during the 2019 Annual Meeting of the American Shoulder and Elbow Surgeons , held Oct. 17-19 in New York.

Metadata
Provider: 
Business Wire, Inc.
Retrieved on: 
Thursday, October 17, 2019
Information
Tags: 
Health, Medical devices, Surgery, Other Health, Managed care, General Health, Biotechnology, Surgery, Medical specialties, Medicine, Shoulder surgery, Surgical specialties, Arthritis, Prosthetics, Shoulder replacement, Orthopedic surgery, Arthroplasty, Shoulder, Catalyst
Geotags: 
United States, Florida
⚠generated by AI ↴
Summary
Key Points: 
  • Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, today announced that William N. Levine, MD will be presenting on the Catalyst CSR Total Shoulder System during the 2019 Annual Meeting of the American Shoulder and Elbow Surgeons , held Oct. 17-19 in New York.
  • Designed by surgeons for surgeons, the Catalyst CSR system is a disruptive technology that represents the next evolution in shoulder surgery.
  • These benefits position the Catalyst CSR system as an attractive solution for anatomic total shoulder replacement surgery.
  • The company's first offering, the Catalyst CSR Total Shoulder System, represents the next evolution in total shoulder arthroplasty.


Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, today announced that William N. Levine, MD will be presenting on the Catalyst CSR™ Total Shoulder System during the 2019 Annual Meeting of the American Shoulder and Elbow Surgeons, held Oct. 17-19 in New York. The session will be at 9:45 am ET on Saturday, Oct. 19 as part of the General Session and is entitled, “A Canal Sparing Total Shoulder Arthroplasty with Multiplanar Osteotomy and Oblique Glenoid Approach.” The session will feature a pre-recorded surgery using the Catalyst CSR system. Dr. Levine is a professor and chair of the Department of Orthopedic Surgery at the Columbia University College of Physicians and Surgeons. He also serves as chief orthopaedic surgeon at New York-Presbyterian/Columbia University Medical Center.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191017005200/en/

Catalyst's new non-spherical humeral component has a titanium plasma spray coating on its patented, bone-facing geometry and uses press-fit fixation for initial stability without the need for bone cement. (Photo: Business Wire)

Catalyst's new non-spherical humeral component has a titanium plasma spray coating on its patented, bone-facing geometry and uses press-fit fixation for initial stability without the need for bone cement. (Photo: Business Wire)

During the ASES meeting, Catalyst will be showcasing the two newest components of its Catalyst CSR system at booth 20 – the Press Fit humeral component and the Augmented Glenoid. These new components expand the application of the Catalyst CSR system, a disruptive technology introduced in 2016.

“We are very honored to have Dr. Levine talk about the Catalyst CSR system during ASES, the largest shoulder meeting of the year,” said Brian K. Hutchison, chairman and CEO of Catalyst. “We are also excited to showcase our two new components, the uncemented Press Fit humeral component and the Augmented Glenoid during this show. Both components are being used clinically by key surgeons, and we are seeing excellent early results.”

Press Fit Humeral Component

The Press Fit humeral component features a non-spherical head, specifically designed to restore the native anatomy of the humeral head and joint kinematics of the shoulder. The new implant has a titanium plasma spray coating on its patented, bone-facing geometry and uses press-fit fixation for initial stability without the need for bone cement. Catalyst continues to offer its original cemented humeral component, which also features the same ellipsoid head design to replicate the native anatomy.

Though extensive research studies have demonstrated that the natural shape of the humeral head is non-spherical, most humeral head implants used in total shoulder arthroplasty today remain as spherical surfaces. The Catalyst CSR system’s ellipsoid humeral components were specifically designed to mimic the shape of a normal human shoulder.

Research to date has suggested that the use of a non-spherical humeral head in total shoulder arthroplasty will have benefits to the patient in both the short and long term. In the short term, the patient may potentially experience improved range of motion and regain the functionality of a healthy shoulder. In the long term, the glenoid component may be exposed to lower stresses and less eccentric loading, potentially reducing wear and the risk of loosening that could ultimately increase the life of the shoulder replacement system.

Augmented Glenoid Component

Catalyst’s unique Augmented Glenoid component was developed for correcting posterior glenoid bone deficiencies. This glenoid implant features the same secure, immediate fixation as the system’s current 3-Peg Glenoid design. The Augmented Glenoid uses the same surgical technique and patented instrumentation as the standard 3-Peg Glenoid, which permits joint access from an oblique approach without the forceful retractions associated with standard shoulder arthroplasty systems.

The Catalyst CSR Total Shoulder System

Designed by surgeons for surgeons, the Catalyst CSR system is a disruptive technology that represents the next evolution in shoulder surgery. The simple surgical technique creates a unique, multiplanar chamfer cut on the humeral head that minimizes bone removal and preserves the strongest, densest bone for the humeral component fixation – similar to modern knee replacement. Patented, angled glenoid instruments aid in the glenoid exposure and lessen retraction on the soft tissue. The precision of the system’s implants and instrumentation yields highly accurate and repeatable restoration of the native non-spherical anatomy. These benefits position the Catalyst CSR system as an attractive solution for anatomic total shoulder replacement surgery.

Today, the Catalyst CSR system has been used in more than 1,300 surgeries. The first patients are more than two years post surgery with excellent clinical results. The system has seen rapid adoption and is supported by a team of top key opinion leaders in the shoulder replacement market.

About Catalyst OrthoScience Inc.

Catalyst OrthoScience develops and markets surgical implants that make orthopedic surgery less invasive and more efficient for both surgeons and patients. Catalyst was founded in 2014 by orthopedic surgeon Steven Goldberg, M.D., who saw the need to make shoulder replacement surgery less invasive and give patients a more natural-feeling shoulder after surgery.

The company's first offering, the Catalyst CSR Total Shoulder System, represents the next evolution in total shoulder arthroplasty. The Catalyst CSR is a single-tray, bone-preserving total shoulder arthroplasty system containing a precision elliptical humeral head and less invasive glenoid component, using specialized ergonomic instrumentation designed for consistent anatomic joint line restoration and glenoid insertion. The Catalyst CSR system can be used in both inpatient and outpatient settings and was cleared for use by the FDA in 2016.

Catalyst OrthoScience has a growing portfolio of 10 granted U.S. patents with several more pending nationally and internationally. The company is headquartered in Naples, Fla., and its products are available across the U.S. For additional information on the company, please visit www.CatalystOrtho.com.

Copyright: 
Copyright Business Wire 2019